Claims for Patent: 10,881,659

Summary for Patent: 10,881,659

Title:	Methods of treating heavy menstrual bleeding
Abstract:	The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-ben- zyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino- )-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.
Inventor(s):	Chwalisz; Kristof (Mundelein, IL), Williams; Laura A. (Gurnee, IL), Jain; Rita I. (Evanston, IL), North; Janine D. (Chicago, IL), Ng; Juki Wing-Keung (Highland Park, IL)
Assignee:	ABBVIE INC. (North Chicago, IL)
Application Number:	14/211,096
Patent Claims:	1. A method for managing heavy menstrual bleeding in a subject suffering from heavy menstrual bleeding, the method comprising orally administering to said subject for a period of at least 84 days (a) 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethylbenz- yl)-4-methyl-2, 6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid as a sodium salt, wherein the sodium salt is administered in an amount equivalent to 600 mg per day of the free acid, wherein the sodium salt is administered twice daily in a first dose equivalent to about 300 mg of the free acid and a second dose equivalent to about 300 mg of the free acid; (b) 1.0 mg per day of estradiol; and (c) 0.5 mg per day of norethindrone acetate; wherein the method reduces the volume of menstrual blood loss in the subject to less than 80 mL per cycle and by at least 50% from baseline. 2. The method of claim 1, wherein the sodium salt is administered for at least 168 days. 3. The method of claim 2, wherein the sodium salt is administered for about 168 days to about 1 year. 4. The method of claim 1, wherein the subject has uterine fibroids. 5. The method of claim 1, wherein the subject does not have uterine fibroids. 6. The method of claim 5, wherein the subject has adenomyosis. 7. A method for managing heavy menstrual bleeding associated with uterine fibroids in a subject in need thereof, the method comprising: orally administering to said subject for a period of at least 84 days (a) 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethylbenz- yl)-4-methyl-2, 6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid as a sodium salt, wherein the sodium salt is administered in an amount equivalent to 600 mg per day of the free acid, wherein the sodium salt is administered twice daily in a first dose equivalent to about 300 mg of the free acid and a second dose equivalent to about 300 mg of the free acid; (b) 1.0 mg per day of estradiol, once daily; and (c) 0.5 mg per day of norethindrone acetate, once daily; wherein the method reduces the volume of menstrual blood loss in the subject to less than 80 mL per cycle and by at least 50% from baseline. 8. The method of claim 7, wherein the sodium salt is administered for at least 84 days and up to about 168 days. 9. The method of claim 7, wherein the estradiol and norethindrone acetate are administered simultaneously with the first or second dose of the sodium salt. 10. A method for managing heavy menstrual bleeding associated with uterine fibroids in a subject in need thereof, the method comprising: orally administering to the subject for a period of at least 84 days and not to exceed 24 months (1) a first dosage form comprising (a) 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethylbenz- yl)-4-methyl-2, 6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid as a sodium salt, wherein the sodium salt is present in the first dosage form in an amount equivalent to 300 mg of the free acid; (b) 1.0 mg of estradiol; and (c) 0.5 mg of norethindrone acetate; and (2) a second dosage form comprising (a) 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethylbenz- yl)-4-methyl-2, 6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid as a sodium salt, wherein the sodium salt is present in the second dosage form in an amount equivalent to 300 mg of the free acid; wherein the first and second dosage forms are each administered once daily and the first and second dosage forms are administered in approximately the morning and evening of each day, respectively; wherein the method reduces the volume of menstrual blood loss in the subject to less than 80 mL per cycle and by at least 50% from baseline. 11. The method of claim 10, wherein the sodium salt is administered for at least 84 days and up to about 168 days. 12. A method for managing heavy menstrual bleeding associated with uterine fibroids in a subject in need thereof, the method comprising: orally administering to said subject for a period of at least 84 days a three drug regimen comprising: (a) 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethylbenz- yl)-4-methyl-2, 6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid as a sodium salt, wherein the sodium salt is administered in an amount equivalent to 600 mg per day of the free acid, wherein the sodium salt is administered twice daily in a first dose equivalent to about 300 mg of the free acid and a second dose equivalent to about 300 mg of the free acid; (b) 1.0 mg per day of estradiol, once daily; and (c) 0.5 mg per day of norethindrone acetate, once daily; wherein the method reduces the volume of menstrual blood loss in the subject to less than 80 mL per cycle and by at least 50% from baseline; and wherein the method limits bone mineral density loss from baseline in the subject to less than 8%. 13. The method of claim 12, wherein the sodium salt is administered for at least 84 days and up to about 168 days. 14. The method of claim 12, wherein the estradiol and norethindrone acetate are administered simultaneously with the first or second dose of the sodium salt. 15. The method of claim 12, wherein the method limits bone mineral density loss from baseline in the subject to less than 5%. 16. The method of claim 12, comprising continuing to orally administer the three drug regimen for a time period as needed to manage the heavy menstrual bleeding associated with uterine fibroids, the time period not to exceed 24 months.